Stanford’s PRIMAvera trial in October 2025 heralds vision’s return for 5 million GA-AMD sufferers, with photovoltaic retinal implants—2x2mm, 30µm thick—enabling 20/546 acuity in 38 end-stage patients, the first reversal of photoreceptor loss via subretinal bionic arrays. Inserted surgically, the device—powered by AR glasses’ near-IR projections—bypasses degenerated maculas, stimulating bipolar cells for central vision restoration up to 3 years post-implant, per NEJM’s 2025 publication.
GA’s untreatable atrophy—leading irreversible blindness in elders—claims 1 million U.S. cases yearly; PRIMA’s 92% fidelity edges Argus II’s obsolescence, with training yielding face/object recognition sans neural plasticity limits. Aalto’s non-damaging laser—activating hormetic heat in RPE—prevents progression in pigs, eyeing human pilots by 2026. Gene therapies like ABBV-RGX-314 induce anti-VEGF for wet AMD reversal, while Luxturna’s inherited cures expand to 20+ mutations.
Oculogenex’s microgravity RPE transplants preserve function 40% better, targeting intermediate AMD’s subtlety. Bond’s cone photoreceptor scaffolds reverse late-stage loss, with 50% over-50s benefiting. As cataracts’ 90% reversibility via surgery underscores treatability, implants’ “learnable vision” opens doors for glaucoma/diabetic retinopathies.
FDA’s 2025 nods could halve 2.2 billion global impairments by 2050, blending bionics with CRISPR for holistic cures.
